HER2+ Breast Cancer Is No Longer a Death Sentence

Modern therapies and specialized approaches have transformed HER2+ breast cancer treatment, offering patients a realistic chance at full recovery and improved quality of life despite its aggressive nature.

Evolution of HER2+ Breast Cancer Treatment

Just over a decade ago, a diagnosis of HER2+ breast cancer was among the most feared. It is one of the most biologically aggressive subtypes of breast cancer, developing rapidly and requiring intensive treatment. However, medicine has taken a huge step forward.

Thanks to modern therapies, many women have a chance at complete recovery, and in advanced cases, they can live for many years while maintaining a good quality of life. Experts point out, however, that the Polish system still does not utilize all the possibilities offered by contemporary oncology, although Poland does have access to many very modern therapies.

Anna Kupiecka, president of the OnkoCafe – Razem Lepiej Foundation, recalls in the Stan Zdrowia podcast that breast cancer is not a single disease, but many different cancers requiring distinct treatments. She was diagnosed with HER2+ breast cancer in 2010 and, from a patient’s perspective, best sees how much treatment options have changed.

Our interviewee emphasizes that when she was ill, statistics looked completely different. Today, doctors have many therapies at their disposal and increasingly tell patients that even with such an aggressive cancer subtype, they have a realistic chance of full recovery.

The Shift Toward Pre-Operative Therapy

Until recently, surgery in breast cancer treatment was perceived as the most important moment of therapy. Meanwhile, modern oncology is increasingly reversing this order, with treatment beginning before the surgical procedure in many patients to shrink the tumor and increase the chances of a successful cure.

As Anna Kupiecka emphasizes, perioperative treatment—both pre- and post-operative—is not merely an addition to surgery, but a key element of the strategy leading to a cure and directly impacting patient survival.

In the case of HER2+ breast cancer, the doctor selects therapy individually, taking into account factors such as tumor size, presence of metastases, lymph node involvement, age of the patient, and coexisting conditions. Systemic treatment is increasingly initiated before surgery, with the surgical procedure performed afterward.

Advances and Gaps in Polish Oncology

In recent years, access to modern breast cancer therapies in Poland has improved significantly, and in many areas, Poland no longer lags behind Western European countries according to Anna Kupiecka. Patients with HER2+ breast cancer today have access to modern dual anti-HER2 blockade in preoperative treatment, which can be administered in a single short subcutaneous injection rather than hours of intravenous infusions.

Anna Kupiecka recalls spending dozens of hours in the chemotherapy ward and notes that receiving treatment subcutaneously back then would have been a massive change.

This solution allows patients to much more easily reconcile therapy with daily life, professional work, and family life, which is particularly important since the highest number of cases occurs in professionally active women.

Unmet Medical Needs in Post-Operative Care

Despite enormous progress, experts point to an unmet medical need affecting women with HER2+ breast cancer and involved lymph nodes.

Currently, patients in Poland can receive dual anti-HER2 blockade before surgery, but this treatment is not continued under public reimbursement after the procedure. Meanwhile, in about 15 European countries, such postoperative therapy is the standard of care.

Anna Kupiecka stresses that this is not merely a matter of treatment comfort, as research results show that continuing intensive therapy after surgery reduces the risk of disease recurrence and premature death in high-risk patients. Therefore, specialists emphasize that this treatment should not be treated as an optional supplement, but as an integral part of permanent recovery.

Medicine is constantly developing, and today we know more than a few years ago, meaning these new data should also be reflected in reimbursement, says Anna Kupiecka.

Impact on Daily Life and Early Detection

The transformation in breast cancer treatment means more than just better clinical outcomes, as an increasing number of women can remain professionally active, enjoy family life, and function normally despite illness.

The president of the OnkoCafe Foundation notes that they have patients who have been undergoing treatment for over a decade and enjoy long-term management because it keeps them alive.

In her view, investing in modern treatment benefits not only the patients but the entire system, as successfully treated women utilize disability pensions and long-term sick leaves less frequently while remaining professionally active and paying contributions.

However, it is worth remembering that even the best therapies cannot replace early cancer detection, and regular mammography or breast ultrasound in appropriate age groups provide the greatest chance of diagnosing the disease at a stage when treatment options are most effective.